CA2376965A1 - Inhibiteurs de la protease du virus de l'hepatite c a base d'acide boronique peptide - Google Patents

Inhibiteurs de la protease du virus de l'hepatite c a base d'acide boronique peptide Download PDF

Info

Publication number
CA2376965A1
CA2376965A1 CA002376965A CA2376965A CA2376965A1 CA 2376965 A1 CA2376965 A1 CA 2376965A1 CA 002376965 A CA002376965 A CA 002376965A CA 2376965 A CA2376965 A CA 2376965A CA 2376965 A1 CA2376965 A1 CA 2376965A1
Authority
CA
Canada
Prior art keywords
substituted
amino
alkyl
acid
heterocyclic ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002376965A
Other languages
English (en)
Inventor
Timothy Patrick Forsyth
Charles A. Kettner
Sharada Jagannathan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Pharma Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2376965A1 publication Critical patent/CA2376965A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1027—Tetrapeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • C12N9/506—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses derived from RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Abstract

La présente invention concerne d'une façon générale de nouveaux acides .alpha.-aminoboroniques et des analogues peptides correspondants représentés par la formule de structure (I) ou l'une de ses formes salines pharmaceutiquement acceptable. Dans cette formule, R?1¿, R?2¿, R?3¿, Y?1¿, Y?2¿, et A sont tels que décrits dans les spécifications. L'invention concerne également, d'une part des formulations pharmaceutiques dont les principes actifs sont les composés de l'invention, et d'autre part l'utilisation de ces composés et de leurs formulations dans le traitement des infections virales de l'hépatite C. Les composés de l'invention sont des inhibiteurs de la protéase virale de l'hépatite C.
CA002376965A 1999-07-07 2000-07-07 Inhibiteurs de la protease du virus de l'hepatite c a base d'acide boronique peptide Abandoned CA2376965A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14256199P 1999-07-07 1999-07-07
US60/142,561 1999-07-07
PCT/US2000/018655 WO2001002424A2 (fr) 1999-07-07 2000-07-07 Inhibiteurs de la protease du virus de l'hepatite c a base d'acide boronique peptide

Publications (1)

Publication Number Publication Date
CA2376965A1 true CA2376965A1 (fr) 2001-01-11

Family

ID=22500325

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002376965A Abandoned CA2376965A1 (fr) 1999-07-07 2000-07-07 Inhibiteurs de la protease du virus de l'hepatite c a base d'acide boronique peptide

Country Status (4)

Country Link
EP (1) EP1196436A2 (fr)
AU (2) AU5920400A (fr)
CA (1) CA2376965A1 (fr)
WO (2) WO2001002601A2 (fr)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6653295B2 (en) 2000-12-13 2003-11-25 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus NS3 protease
WO2002048116A2 (fr) * 2000-12-13 2002-06-20 Bristol-Myers Squibb Pharma Company Inhibiteurs de la protease ns3 du virus de l'hepatite c
AU2002243508A1 (en) 2001-01-10 2002-07-24 Bristol-Myers Squibb Company Patent Department Alpha-aminoboronic acids prepared by novel synthetic methods
WO2002059131A1 (fr) 2001-01-25 2002-08-01 Millennium Pharmaceuticals, Inc. Formulation de composes d'acide boronique
US7119072B2 (en) 2002-01-30 2006-10-10 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis C virus
US7091184B2 (en) 2002-02-01 2006-08-15 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
US6642204B2 (en) 2002-02-01 2003-11-04 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
US20050288253A1 (en) 2002-09-09 2005-12-29 Trigen Limited Boronic acid salts
SI1400245T1 (sl) 2002-09-09 2006-10-31 Trigen Ltd Soli boronske kisline, uporabne v parenteralnih formulacijah za selektivno inhibiranje trombina
US20050075279A1 (en) 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
AU2011203054B2 (en) * 2003-04-11 2012-04-26 Vertex Pharmaceuticals, Incorporated Inhibitors of Serine Proteases, Particularly HCV NS3-NS4A Protease
US20050090450A1 (en) * 2003-04-11 2005-04-28 Farmer Luc J. Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
US7405210B2 (en) 2003-05-21 2008-07-29 Osi Pharmaceuticals, Inc. Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
PL1654261T3 (pl) 2003-05-21 2008-04-30 Boehringer Ingelheim Int Związki hamujące aktywność wirusa zapalenia wątroby typu C
US20050136394A1 (en) * 2003-06-23 2005-06-23 Hong Fang Cell-based assay for identifying peptidase inhibitors
US7576206B2 (en) 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7223745B2 (en) 2003-08-14 2007-05-29 Cephalon, Inc. Proteasome inhibitors and methods of using the same
AR045596A1 (es) * 2003-09-05 2005-11-02 Vertex Pharma Inhibidores de proteasas de serina en particular proteasa ns3-ns4a del vhc
PE20050431A1 (es) 2003-09-22 2005-07-19 Boehringer Ingelheim Int Peptidos macrociclicos activos contra el virus de la hepatitis c
EP1730167B1 (fr) 2004-01-21 2011-01-12 Boehringer Ingelheim International GmbH Peptides macrocycliques actifs contre le virus de l'hepatite c
ATE483708T1 (de) 2004-03-08 2010-10-15 Prosidion Ltd Pyrrolopyridin-2-carbonsäurehydrazide als inhibitoren von glykogenphosphorylase
WO2006085932A2 (fr) 2004-06-14 2006-08-17 Anacor Pharmaceuticals, Inc. Utilisations antivirales de complexes d'acide borinique
UY29016A1 (es) 2004-07-20 2006-02-24 Boehringer Ingelheim Int Analogos de dipeptidos inhibidores de la hepatitis c
CA2573346C (fr) 2004-07-20 2011-09-20 Boehringer Ingelheim International Gmbh Analogues peptidiques inhibiteurs de l'hepatite c
DE602005013275D1 (de) 2004-12-02 2009-04-23 Prosidion Ltd Pyrrolopyridin-2-karbonsäureamide
US7468383B2 (en) 2005-02-11 2008-12-23 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US20060264415A1 (en) * 2005-04-01 2006-11-23 Methylgene Inc. Inhibitors of histone deacetylase
EP1915382A2 (fr) * 2005-08-01 2008-04-30 Phenomix Corporation Inhibiteurs de la sérine protéase de l'hépatite c et emploi desdits inhibiteurs
WO2007137080A2 (fr) 2006-05-23 2007-11-29 Irm Llc Composés et compositions en tant qu'inhibiteurs de protéases activatrices de canal
EP1886685A1 (fr) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes, utilisations et compositions pour la modulation de la réplication du HCV par activation ou inhibition du récepteur farnesoid X
US20100120716A1 (en) * 2006-12-06 2010-05-13 Phenomix Corporation Macrocyclic hepatitis c serine protease inhibitors and uses therefor
MX2009008518A (es) 2007-02-09 2009-08-20 Irm Llc Compuestos y composiciones como inhibidores de la proteasa activadora de canal.
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
US7838673B2 (en) 2007-10-16 2010-11-23 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
SI2318419T1 (sl) 2008-06-17 2015-07-31 Millennium Pharmaceuticals, Inc. Spojine boronat estra in njihovi farmacevtski sestavki
AR075090A1 (es) 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
WO2011087822A1 (fr) 2009-12-22 2011-07-21 Cephalon, Inc. Inhibiteurs du protéasome et leurs procédés de préparation, d'épuration et d'utilisation
WO2011103063A1 (fr) * 2010-02-19 2011-08-25 Glaxo Group Limited Composés thérapeutiques
RU2012146101A (ru) 2010-03-31 2014-05-10 Милленниум Фармасьютикалз, Инк. Производные 1-амино-2-циклопропилэтилбороновой кислоты
AU2011329485A1 (en) * 2010-11-18 2013-04-18 Glaxo Group Limited Compounds
WO2012107589A1 (fr) 2011-02-11 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et compositions pharmaceutiques pour le traitement et la prévention des infections à vhc
KR101975233B1 (ko) * 2011-08-17 2019-05-07 글락소스미스클라인 엘엘씨 치료 방법
HUE030300T2 (en) * 2011-08-19 2017-04-28 Glaxo Group Ltd Benzofuran Compounds for the treatment of hepatitis C virus infections
US10092574B2 (en) 2012-09-26 2018-10-09 Valorisation-Recherche, Limited Partnership Inhibitors of polynucleotide repeat-associated RNA foci and uses thereof
UA121389C2 (uk) 2014-05-20 2020-05-25 Мілленніум Фармасьютікалз, Інк. Борвмісні інгібітори протеасом для застосування після первинної протиракової терапії
EP3201208B1 (fr) * 2014-10-01 2021-03-24 Merck Patent GmbH Dérivés d'acide boronique
AU2015327345B9 (en) * 2014-10-01 2020-06-18 Merck Patent Gmbh Boronic acid derivatives
AU2015327346B2 (en) * 2014-10-01 2019-12-05 Merck Patent Gmbh Boronic acid derivatives
WO2017222914A1 (fr) 2016-06-21 2017-12-28 Inception 4, Inc. Dérivés de prolinamide carbocycliques
PT3472149T (pt) 2016-06-21 2023-11-23 Orion Opthalmology Llc Derivados de prolinamida heterocíclicos
BR112023018321A2 (pt) 2021-03-15 2024-01-02 Maze Therapeutics Inc Inibidores de glicogênio sintase 1 (gys1) e métodos de uso dos mesmos

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5599906A (en) * 1990-04-13 1997-02-04 Schering Corporation Protease assays
IT1272179B (it) * 1994-02-23 1997-06-16 Angeletti P Ist Richerche Bio Metodologia per riprodurre in vitro l'attivita' proteolitica della proteasi ns3 del virus hcv.
US5861267A (en) * 1995-05-01 1999-01-19 Vertex Pharmaceuticals Incorporated Methods, nucleotide sequences and host cells for assaying exogenous and endogenous protease activity
KR100209095B1 (ko) * 1996-06-28 1999-07-15 성재갑 C형 간염 바이러스의 프로테아제의 활성을 측정할 수 있는 c형 간염 대체 바이러스, 그 재조합 유전자 및 그 용도
CZ298749B6 (cs) * 1996-10-18 2008-01-16 Vertex Pharmaceuticals Incorporated Inhibitory serinových proteáz a farmaceutické prostředky s jejich obsahem
GB9623908D0 (en) * 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
WO1998037180A2 (fr) * 1997-02-22 1998-08-27 Abbott Laboratories Protease hybride du vhc et polynucleotide codant cette derniere
ES2241157T3 (es) * 1997-08-11 2005-10-16 Boehringer Ingelheim (Canada) Ltd. Peptidos inhibidores de la hepatitis c.
US6280940B1 (en) * 1998-08-05 2001-08-28 Agouron Pharmaceuticals, Inc. Reporter gene system for use in cell-based assessment of inhibitors of the Hepatitis C virus protease
DK1177211T3 (da) * 1999-05-04 2008-06-02 Boehringer Ingelheim Ca Ltd Surrogatcellebaseret system og fremgangsmåde til at analysere aktiviteten for Hepatitis C-virus NS3-protease

Also Published As

Publication number Publication date
WO2001002424A2 (fr) 2001-01-11
AU5788800A (en) 2001-01-22
WO2001002424A3 (fr) 2001-07-19
WO2001002601A2 (fr) 2001-01-11
WO2001002601A3 (fr) 2001-07-26
AU5920400A (en) 2001-01-22
EP1196436A2 (fr) 2002-04-17

Similar Documents

Publication Publication Date Title
CA2376965A1 (fr) Inhibiteurs de la protease du virus de l'hepatite c a base d'acide boronique peptide
US6846806B2 (en) Peptide inhibitors of Hepatitis C virus NS3 protein
US6727366B2 (en) Imidazolidinones and their related derivatives as hepatitis C virus NS3 protease inhibitors
US6774212B2 (en) Alpha-ketoamide inhibitors of hepatitis C virus NS3 protease
US6699855B2 (en) Inhibitors of hepatitis C virus NS3 protease
US6653295B2 (en) Inhibitors of hepatitis C virus NS3 protease
AU757072B2 (en) Hepatitis C inhibitor peptide analogues
US7122627B2 (en) Lactam inhibitors of Hepatitis C virus NS3 protease
FI120974B (fi) Booriesteri- ja -happoyhdisteet sekä näiden käyttö
US5658885A (en) Amidino and guanidino substituted boronic acid inhibitors of trypsin-like enzymes
ES2241157T3 (es) Peptidos inhibidores de la hepatitis c.
WO2002048116A2 (fr) Inhibiteurs de la protease ns3 du virus de l'hepatite c
WO2001007407A1 (fr) Inhibiteurs lactame de la protease ns3 du virus de l'hepatite c
SK2052001A3 (en) Peptide analogues, process for their preparation, pharmaceutical composition containing same, their use and intermediates
MXPA00001491A (en) Hepatitis c inhibitor peptide analogues

Legal Events

Date Code Title Description
FZDE Dead